US FDA approves Jardiance to treat adults living with heart failure with reduced ejection fraction
Heart failure accounts for more than one million hospitalisations a year in the US
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
EMPEROR-Reduced Phase III trial
Empagliflozin meets primary endpoint in Phase III heart failure trial
It reduced the risk of cardiovascular death or hospitalisation for heart failure versus placebo on top of standards of care in…